Skip to main content

Table 1 Patient characteristics when starting hepatitis C (HCV) treatment with daclatasvir (n = 249)

From: The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease

Characteristics All Genotype Ribavirin
  1a 3b Otherc With Without
n = 249 n = 187 n = 40 n = 22 n = 66 n = 183
Age, median (years) 56 56 55 55 55 57
Male (%) 78 75 85 91 85 76
HIV co-infection (%) 10 8 15 14 11 9
Prior HCV treatment (%) 65 69 48 64 65 65
Cirrhosis (%)
 - No 14 16 5 14 18 13
 - Compensated 27 21 48 36 27 26
 - Decompensated 59 63 48 50 55 61
Child Pugh class (%)
 - A 27 27 20 41 29 26
 - B 33 37 23 14 33 32
 - C 8 9 3 9 5 9
 - Unknown 33 27 55 36 33 32
Fibrosis stage (%)
 - < F3 9 9 5 14 9 9
 - F3 – F4 82 83 73 82 82 81
 - Unknown 10 8 23 5 9 10
Hepatocellular carcinoma (%)
 - Never 58 56 65 68 61 57
 - Past 17 19 13 14 18 17
 - Current 12 13 10 9 15 12
 - Unknown 12 12 13 9 6 14
Liver transplantation (%)
 - Never 34 31 50 32 27 36
 - On list 13 14 13 9 11 14
 - Before current treatment 40 40 33 50 44 38
 - During current treatment 11 13 3 9 12 10
 - Unknown 2 3 3 0 6 1
  1. aGenotypes 1 (n = 14), 1a (n = 58), 1a/b (n = 3), and 1b (n = 112)
  2. bGenotypes 3 (n = 18), 3a (n = 21) and 3 h (n = 1)
  3. cGenotypes 2 (n = 4), 4 (n = 17) and 5 (n = 1)